Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2651MR)

This product GTTS-WQ2651MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2651MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15187MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ2264MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ13221MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ1226MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ1138MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ11366MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ1492MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ2879MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW